leadf
logo-loader
viewArecor Therapeutics PLC
(
AIM:AREC
)

Arecor licenses first formulation to partner Inhibrx, taking their lung disease product to clinic

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Katie Pilbeam about their peer review paper on their first clinical trial of proprietary product, AT247, which has been published in the prestigious medical journal Diabetes Care.

In terms of news flow, their first patient has been dosed in a phase 1 clinical trial for their second product, AT278, a new ultra-concentrated rapid insulin.

And their partner INHIBRX has licensed an option to take their liquid formulation of their product to the clinic.

Quick facts: Arecor Therapeutics PLC

Follow
AIM:AREC

Price: 323.4 GBX

Market Cap: £89.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Arecor list in London and 'look forward to delivering on exciting next phase...

Arecor Therapeutics' (LON:AREC) CEO Sarah Howell joins Proactive London on the first day of their London listing. The firm has raised £20 million in the oversubscribed IPO, receiving strong support from investors. Howell explains what the money will be used for, progressing their lead...

on 3/6/21

2 min read